Abstract
MHC Class II deficiency is a rare primary immunodeficiency disease characterized by absent HLA Class II expression resulting in CD4 lymphopenia, lack of Ag-specific responses and recurrent infection. Without successful allogeneic SCT, most children succumb to infection within the first decade of life. To date, alternative donor transplants for this disorder have been inferior to SCT for other forms of combined immunodeficiency disease due to an increased incidence of graft rejection, GVHD and death from infections generally acquired before haematopoietic cell transplantation. This study details the transplant outcome of 16 affected children consecutively transplanted at four centers since 1990, 8 of whom required mechanical ventilation pretransplant. Stem cells were derived from an HLA-mismatched family member (n=10), an HLA-matched unrelated adult donor (n=4), or an unrelated cord blood donor (n=2). Graft failure occurred in five children, all of whom underwent a second SCT. Six patients developed acute GVHD although no patient developed chronic GVHD after primary transplantation. CD4 T-cell reconstitution remained below the normal range for age, suggesting defective thymopoiesis after allo-SCT. Nonetheless, 69% of children survive without GVHD at a median follow-up of 5.7 years, indicating improved outcomes compared with previous studies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Elhasid R, Etzioni A . Major histocompatibility complex class II deficiency: a clinical review. Blood Rev 1996; 10: 242–248.
Reith W, Mach B . The Bare lymphocyte syndrome and the regulation of MHC Expression. Annu Rev Immunol 2001; 19: 331–373.
Villard J, Masternak K, Lisowska-Grospierre B, Fischer A, Reith W . MHC class II deficiency: a disease of gene regulation. Medicine 2001; 80: 405–418.
Saleem MA, Arkwright PD, Davies EG, Cant AJ, Veys PA . Clinical course of patients with major histocompatibility complex class II deficiency. Arch Dis Child 2000; 83: 356–359.
Klein C, Klein C, Lisowska-Grospierre B, LeDeist F, Fischer A, Griscelli CJ . Major histocompatibility complex class II deficiency: clinical manifestations, immunologic features, and outcome. J Pediatr 1993; 123: 921–928.
Klein C, Cavazzana-Calvo M, Frangoise Le Deist F, Jabado N, Benkerrou M, Blanche S et al. Bone marrow transplantation in major histocompatibility complex class II deficiency: a single-center study of 19 patients. Blood 1995; 85: 580–587.
Ouederni M, Vincent QB, Frange P, Touzot F, Scerra S, Bejaoui M et al. Major histocompatibility complex class II expression deficiency caused by a RFXANK founder mutation: a survey of 35 patients. Blood 2011; 118: 5108–5118.
Al-Ghonaium A . Stem cell transplantation for primary immunodeficiencies: King Faisal Specialist Hospital experience from 1993 to 2006. Bone Marrow Transplant 2008; 42: S53–S56.
Al-Mousa H, Al-Shammari Z, Al Ghonaium A, Al-Dhekri H, Al-Muhsen S, Al-Saud B et al. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency. Biol Blood Marrow Transplant 2010; 16: 818–823.
Renella R, Picard C, Neven B, Ouachee-Chardin M, Casanova J-L, Le Deist F et al. Human leucocyte antigen-identical haematopoietic stem cell transplantation in major histocompatibility complex class II immunodeficiency: reduced survival correlates with an increased incidence of acute graft-versus-host disease and preexisting viral infections. Br J Haematol 2006; 134: 510–516.
Bonduel M, Del Pozo A, Zelazko M, Raslaswki E, Delfino S, Rossi J et al. Successful related umbilical cord blood transplantation for graft failure following T cell-depleted non-identical bone marrow transplantation in a child with major histocompatibility complex class II deficiency. Bone Marrow Transplant 1999; 24: 437–440.
Bonduel M, Staciuk R, Figueroa C, Oleastro M, Gamba C, Rossi J et al. Unrelated cord blood transplantation and reduced-intensity conditioning regimen for graft failure in a child with major histocompatibility complex class II deficiency. Bone Marrow Transplant 2009; 43: 817–818.
Chiesa R, Gilmour K, Qasim W, Adams S, Worth AJ, Zhan H et al. Omission of in vivo T-cell depletion promotes rapid expansion of naïve CD4 cord blood lymphocytes and restores adaptive immunity within two months after unrelated cord blood transplant. Br J Haematol 2012; 156: 656–666.
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.
Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267–276.
Shearer WT, Rosenblatt HM, Gelman S, Oyomopito R, Plaeger S, Stiehm ER et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol 2003; 112: 973–980.
Small TN, Friedrich W, O’Reilly RJ . Hematopoietic cell transplantation for immunodeficiency diseases. In: Forman S, Blume KG, Thomas ED, (eds). Hematopoietic Cell Transplantation 4th edn vol. 75. Blackwell Science: Malden, MA, 2009 pp 1105–1124.
Grusby MJ, Glimcher LH . Immune responses in MHC class II-deficient mice. Ann Rev Immunol 1995; 13: 417–435.
Munchel A, Kesserwan C, Symons HJ, Luznik L, Kasamon YL, Jones RJ et al. HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide. Pediatr Rep 2011; 3 (Suppl 2): e15.
Li W, Kim M-G, Gourley TS, McCarthy BP, Sant’Angelo DB, Chang CH . An alternate pathway for CD4 T cell development: thymocyte-expressed MHC class II selects a distinct T cell population. Immunity 2005; 23: 375–386.
Acknowledgements
We are grateful to all the nurses and physicians dedicated to the care of these children.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Small, T., Qasim, W., Friedrich, W. et al. Alternative donor SCT for the treatment of MHC Class II deficiency. Bone Marrow Transplant 48, 226–232 (2013). https://doi.org/10.1038/bmt.2012.140
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2012.140